Quarterly ResultMay 7, 2026, 04:23 PM
Evommune Q1 Net Loss $21.7M; EVO756 Phase 2b Data on Track
AI Summary
Evommune, Inc. reported its first-quarter 2026 financial results, including a net loss of $21.7 million, compared to $14.6 million in Q1 2025. The company also provided a business update, confirming that top-line Phase 2b data for EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) are on track for June 2026 and Q3 2026, respectively. Evommune plans to initiate a Phase 2b trial for EVO756 in migraine prophylaxis in mid-2026 and a Phase 2b trial for EVO301 in AD in mid-2027, supported by a strong cash position of $307.0 million, expected to fund operations through 2028.
Key Highlights
- Net loss for Q1 2026 was $21.7 million, compared to $14.6 million in Q1 2025.
- Cash, cash equivalents, and investments totaled $307.0 million as of March 31, 2026, providing runway through 2028.
- EVO756 Phase 2b top-line data for chronic spontaneous urticaria expected in June 2026 and for atopic dermatitis in Q3 2026.
- Enrollment is complete for both EVO756 Phase 2b trials in CSU (N=160) and AD (N=120).
- Plans to initiate a Phase 2b trial for EVO756 in migraine prophylaxis in mid-2026.
- Phase 2b trial for subcutaneous EVO301 in atopic dermatitis planned for mid-2027, following positive Phase 2a POC data.
- Research and development expenses increased to $17.3 million from $14.4 million year-over-year.
- Revenue was zero for Q1 2026, down from $3.0 million in Q1 2025.